Actuarial Modelling for Patients with Acute Lymphoblastic Leukaemia (ALL) based on CNS1 Status

Introduction: Worldwide, Acute Lymphoblastic Leukaemia (ALL) is the most frequent cancer in children. One of major clinical challenges adequate diagnosis and treatment Central Nervous System (CNS) involvement this disease. CNS relapse has been a barrier to successful ALL for many years. Recent studies have shown encouraging results survival these patients long time. However, their long-term depends upon cost therapy toxicity financial distress. The primitive aim paper propose yearly insurance plan assist financially during period. Method: Based on status 110 are categorised estimate survival. Survival times CNS1 all cumulatively estimated by Kaplan-Meier Cox-PH model presence prognostic factors. estimates used premium cost. using deterministic which advantageous patient serviceable provider. Result: Both methods gave higher as compared CNS1. from 0.998 0.997 first year follow-up taken respectively. For fifth 0.802 0.783 100 rupees sum insured 4.7 26.69 cumulatively. Same CNS1, it 6.24 29.42. Conclusion: estimating recommended since includes suggests opt early possibly costs less increases later.